Company Overview and News

5
China’s luck on yuan devaluation risks running out on Trump ire

4h malaymail
HONG KONG, July 22 — For more than a month, China seemed to be enjoying the advantage of exchange-rate depreciation without the global backlash and panicky capital outflows that accompanied the bout of yuan weakening in 2015. Then Donald Trump took issue.
GS.PRB MS.PRE GS.PRA MS.PRF MS.PRG MS.PRA HSB GS GLSSP HSBC.PRA MS HSBC HBCYF HCS.PRB JBK GSC GS.PRICL TFG HCS GSJ GS.PRJ 0005 GS.PRI MS.PRI GS.PRD MS.PRK GS.PRC HSEA HSEB GJS GS.PRN GS.PRK

0
Michael Manley new man at Fiat after revving up Jeep

16h malaymail
WASHINGTON, July 22 — Michael Manley, named yesterday to replace Sergio Marchionne as chief of Fiat Chrysler (FCA), is the 54-year-old head of the group’s Jeep brand, where he managed to push sales through the one-million mark last year.
MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA

0
Fiat turn to Jeep’s Manley to replace ailing Marchionne

17h malaymail
ROME, July 22 — Fiat Chrysler (FCA) said that its chief, Sergio Marchionne, is stepping down due to ill health and will be replaced by Mike Manley, head of the group’s Jeep brand.
MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA

0
Flash - Fiat turn to Jeep's Manley to replace ailing Marchionne - France 24

18h france24
Fiat Chrysler (FCA) said that its chief, Sergio Marchionne, is stepping down due to ill health and will be replaced by Mike Manley, head of the group's Jeep brand.
MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA

0
New Fiat Chrysler boss transformed Jeep brand as company focuses on SUVs

18h reuters
WASHINGTON, July 21 (Reuters) - Fiat Chrysler Automobiles NV’s new chief executive Mike Manley, who has overseen the effort to turn Jeep into a global brand, now plans to carry out the parent company’s strategy unveiled last month, the company said Saturday.
MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS DDAIF MS.PRA

0
New Fiat Chrysler boss transformed Jeep brand as company focuses on SUVs

18h reuters
WASHINGTON (Reuters) - Fiat Chrysler Automobiles NV’s (FCHA.MI) new chief executive Mike Manley, who has overseen the effort to turn Jeep into a global brand, now plans to carry out the parent company’s strategy unveiled last month, the company said Saturday.
MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS DDAIF MS.PRA

29
U.S. IPO Week Ahead: Tech, Tech, And More Tech With 11 U.S. IPOs Planned For This Coming Week

2018-07-21 seekingalpha
11 IPOs are expected to price this week, making it another busy one, and totaling $3.4 billion in combined proceeds. A whopping six tech deals are pricing, including three from China. Chinese e-commerce giant Pinduoduo is the week's largest deal, raising $1.5 billion. US cybersecurity play Tenable should get the most attention - almost every enterprise software IPO with its profile has been a homerun.
DB BRY MS.PRE MS.PRF MS.PRG MS.PRA IPO MS.PRI SPOT MS.PRK MS IPOS SNAP

0
Idiosyncratic Small-Cap Stocks: How To Manage Volatility

2018-07-21 seekingalpha
A fundamental reason people invest in small caps is their potential for better returns over longer periods. Small caps as an asset class tend to be more growth oriented, and thus investors may stand to gain more from allocating to small caps. However, higher volatility is inherent to U.S. small caps too.
RPUT MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA

0
Platform Specialty Products Corp (PAH) Announcing Sale of Arysta LifeScience and a New Chapter Confernece Call (Transcript)

2018-07-21 seekingalpha
Platform Specialty Products Corp (NYSE:PAH) Announcing the Sale of Arysta LifeScience and a New Chapter Conference Call July 20, 2018 8:30 AM ET
MS.PRI PAH MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA

1
State Street Corporation (STT) CEO Jay Hooley on Q2 2018 Results - Earnings Call Transcript

2018-07-20 seekingalpha
Good morning, and welcome to State Street Corporation's Second Quarter of 2018 Earnings Conference Call and Webcast. Today's discussion is being broadcast live on State Street's website at investors.statestreet.com.
STT STT.PRC STT.PRE STT.PRD MS.PRE STT.PRG MS.PRF MS.PRG MS.PRA MS.PRI MS.PRK 3772 MS

0
Faurecia's (FURCF) CEO Patrick Koller on Half Year 2018 Results - Earnings Call Transcript

2018-07-20 seekingalpha
Welcome to the presentation of our first half 2018 results. I propose to give you the highlights of this first half. Michel Favre will then detail our H1 2018 results, and I will close this presentation with our upgraded guidance.
DB MS.PRI SCGLF MS.PRK MS.PRE MS.PRF SCGLY MS.PRG GLE MS MS.PRA

54
Bank ETFs Rise on the Wave of Big Releases

2018-07-20 zacks
The financial sector, which accounts for around one-fifth of the S&P 500 index, is now busy with Q2 earnings releases. The going is great so far, with five big banks crushing estimates on both lines and one reporting mixed results. The backdrop should favor the banks along with the course of oil, the stance taken by the Fed and the proposed policies of Trump (read: How Financial ETFs Look After Fed Stress Test).
WFCNP C.WSA MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA BAC WFC.PRT C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV C.PRS WFC WFC.WS BAC C VFH C.PRL IYG C.PRJ C.PRK C.PRG C.PRC MS.PRI C.PRPCL MS.PRK CGBBW

0
3 Casino Stocks to Buy Now

2018-07-20 zacks
Perhaps it is because trading stocks can often mirror the thrill of winning big at the blackjack tables, or maybe it is because Las Vegas conjures images of the world’s most flashy brands and businessmen. Regardless of the reason, it is clear that gambling stocks are always among the most popular on Wall Street.
MS.PRI MS.PRK MS.PRE MS.PRF PENN MS.PRG MS RRR MS.PRA BYD

0
Kansas City Southern (KSU) CEO Patrick Ottensmeyer on Q2 2018 Results - Earnings Call Transcript

2018-07-20 seekingalpha
Greetings and welcome to the Kansas City Southern Second Quarter 2018 Earnings Call. At this time, all participants will be in a listen-only mode. A brief question-and-answer session will follow the formal presentation.
MS.PRI MS.PRK KSU.PR MS.PRE MS.PRF MS.PRG MS MS.PRA KSU

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 61762V507